Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Completes $12M Public Offering

NEW YORK (GenomeWeb News) – CombiMatrix today said it has closed its public offering of 12,000 units of Series D convertible preferred stock and warrants, raising $12 million in gross proceeds.

The units were priced at $1,000 each, and consisted of one share of Series D convertible preferred stock — which can be converted into 485.4369 shares of common stock at a conversion price of $2.06 per share — and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share.

The array-based molecular diagnostic company disclosed its offering in September and priced its offering earlier this week.

Net proceeds from the offering are anticipated to be about $10.8 million, CombiMatrix said. Ladenburg Thalmann was the underwriter on the offering,

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.